Dr. Jorge Mallea, MD

Dr. Mallea practices at Mayo Clinic Hospital in Jacksonville, Florida, part of Mayo Clinic.

Dr. Mallea's NPI, 1306825781, was assigned on January 12, 2006. Dr. Mallea graduated from National University of St. Augustin of Arequipa - Faculty of Medicine in 1993. Dr. Mallea holds Florida license ME109516.

Dr. Mallea's primary practice is Mayo Clinic Hospital, at 4500 San Pablo Rd, Jacksonville, FL 32224 in Duval County. The practice phone is (904) 953-2000.

Dr. Mallea's primary practice is Mayo Clinic Hospital in Jacksonville, Florida, part of Mayo Clinic. The medical group on file is Mayo Clinic Jacksonville.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mallea practices. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Mallea's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Mallea is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Mallea's licenses on file in 3 states: Florida, North Carolina and New York.

Dmand AI lists acute respiratory failure, chronic obstructive pulmonary disease (COPD), chronic respiratory failure, pleural effusion and pneumonia among the conditions Dr. Mallea treats.

CMS data shows 136 Medicare services from Dr. Mallea across 1 procedure code in 2024, for 80 Medicare patients. Medicare paid $22,594 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 80 Medicare patients who saw Dr. Mallea in 2024. The largest group is 65 to 74, with 33 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 3.42, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mallea's median patient age at 69, with 32% women.

In 2023, Dr. Mallea wrote 30 Medicare Part D claims. They cover 2 drugs, with $20,603 in total drug cost. In 2022, CMS named 287 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Mallea for performance year 2024, reported as part of a group. Dr. Mallea accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 36 papers to Dr. Mallea, published from 2012 to 2025. 2020 was the busiest year, with 10. The most frequent topics are Lung Transplantation, Lung and COVID-19. Dr. Mallea has published most often in J Heart Lung Transplant. Dr. Mallea's most frequent co-authors are David Brett Erasmus, MD, Augustine S. Lee, MD and Cesar Ariel Keller, MD.

Dmand AI links Dr. Mallea to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema and Emphysema. Open Payments lists research payments to Dr. Mallea that name 1 trial.

CMS Open Payments shows 53 general payments to Dr. Mallea from 6 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 98% of the total. United Therapeutics Corporation paid the most, $453,257. It also lists 9 research payments totaling $14,136 from 2024 to 2025, naming 1 clinical trial.

Dr. Mallea graduated from National University of St. Augustin of Arequipa - Faculty of Medicine in 1993.

Dr. Mallea is in network with 9 carriers, including Elevance, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. POS plans come from the most carriers, 5. Check the plan with the practice before a visit.